Masatoshi Kudo

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma”.

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

New England Journal of Medicine(2020)10.1056/nejmoa1915745

N/A

1.3DataRank · unranked

7029 citations

Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux, Tae-You Kim +19 more

E7386 Enhances Lenvatinib’s Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0725

N/A

0.282DataRank · unranked

5 citations

Albert Gris‐Oliver, Ugne Balaseviciute, Alka A. Potdar, Takayuki Kimura, Jialing Shen +21 more

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

European Journal of Cancer(2022)10.1016/j.ejca.2022.08.024

N/A

0DataRank · unranked

112 citations

Jaekyung Cheon, Antonio D’Alessio, Naoshi Nishida, Celina Ang, Thomas U. Marron +32 more

Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma

Nature Reviews Clinical Oncology(2024)10.1038/s41571-024-00868-0

N/A

0DataRank · unranked

346 citations

Roser Pinyol, Mark Yarchoan, Amit G. Singal, Thomas U. Marron, Myron E. Schwartz +4 more

Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study

JHEP Reports(2025)10.1016/j.jhepr.2025.101685

N/A

0DataRank · unranked

2 citations

Tiziana Pressiani, Naoshi Nishida, Shadi Chamseddine, Ashwini Arvind, Michael Li +36 more

Breakthroughs in Hepatocellular Carcinoma Therapies

Clinical Gastroenterology and Hepatology(2023)10.1016/j.cgh.2023.01.039

N/A

0DataRank · unranked

155 citations

Masatoshi Kudo, Jordi Bruix, Amit G. Singal

Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

Hepatology(2020)10.1002/hep.31327

N/A

0DataRank · unranked

414 citations

Augusto Villanueva, Jorge A. Marrero, Myron E. Schwartz, Tim Meyer, Peter R. Galle +9 more